leadf
logo-loader
viewSynairgen PLC

Synairgen's Richard Marsden details expansion of home-based coronavirus trial

Synairgen PLC's (LON:SNG) Richard Marsden says a trial of its treatment for people with coronavirus (COVID-19) is being expanded nationally with participants receiving the inhaled drug in their homes.

He says results from the study of 100 patients successfully treated with the SNG001 treatment in hospital are set to be released next month.

Details for those interested in taking part in the home trial can be found at www.covidtrialathome.com

Quick facts: Synairgen PLC

Price: 167 GBX

AIM:SNG
Market: AIM
Market Cap: £333.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read